Samsung Biologics
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Samsung Biologics is a contract manufacturer of biologic medicines, meaning it produces drugs on behalf of pharmaceutical and biotech companies rather than marketing its own branded therapies.
It runs large-scale facilities that make antibody and other protein-based treatments under contract, and it also offers drug-development support services. Global drugmakers use its capacity to scale up production. The company is part of South Korea's Samsung group.
Summary is AI-generated and may contain errors · figures from DART filings
It belongs to the Samsung group and is one of several Samsung affiliates active in healthcare and biotechnology.
Samsung Biologics in five facts
What does Samsung Biologics do?
Samsung Biologics is a contract manufacturer of biologic medicines, meaning it produces drugs on behalf of pharmaceutical and biotech companies rather than marketing its own branded therapies.
Where is Samsung Biologics listed and in which sector?
Samsung Biologics (Korean name: 삼성바이오로직스) trades under KRX code 207940 on KOSPI, the main board of the Korea Exchange. It is classified in the Health Care sector, Pharmaceuticals.
How large is Samsung Biologics?
Its market capitalisation was US$49.5B on 2026-10-21, which puts it in this site's large-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Samsung Biologics's latest annual revenue and operating profit?
For fiscal year 2025, Samsung Biologics reported revenue of US$3.4B, operating profit of US$1.6B and net income of US$1.3B, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 0.2% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- [Amended] DisclosureOct 21
- Operating results (consolidated) (preliminary) (fair disclosure)
Samsung Biologics filed provisional (unaudited) consolidated results for Q3 2026: revenue of US$1.12B (+18.5% year on year), operating profit of US$482M (+1% year on year) and net income of US$295M (−21.2% year on year).
Earnings · Oct 21 - [Amended] Decision to acquire shares/equity in another company (subsidiary)
Samsung Biologics updated the disclosed terms of a subsidiary's acquisition of PolyPeptide Group AG, now worth US$2.01B.
M&A · Oct 16 · 2 versions - [Amended] Material event report (equity acquisition)M&A · Oct 16 · 3 versions
- Earnings release schedule notice (notice)Oct 7
- Change in shares held by the largest shareholderOct 6
- Supply contract signed (voluntary)
Samsung Biologics disclosed a supply contract, worth US$69.6M, about 2.05% of its recent annual revenue, running through Dec 2031.
Supply contract · Oct 2 - Rights offering: new share issue price (notice)
Samsung Biologics announced a 1st issuance price of US$862.86 per common share for its rights offering as of the new-share record date, with the confirmed issuance price to be determined and disclosed on November 5, 2026 under a formula using the lower of two reference prices with a 15% discount.
Capital raise · Oct 1 - [Amended] ProspectusOct 1
- [Terms finalized] Securities registration statement (equity)Oct 1
- [Amended] Material event report (rights offering)
Samsung Biologics updated the terms of a new share issuance to raise US$2.21B, about 5.0% of its market value.
Capital raise · Oct 1 · 2 versions - ProspectusSep 14
- DisclosureSep 14
- [Amended] Securities registration statement (equity)Sep 11
- [Amended] Supply contract signed
Samsung Biologics updated a previously disclosed supply contract, now worth US$365M, about 105.89% of its recent annual revenue, running through Dec 2028.
Supply contract · Sep 10 - Supply contract signed
Samsung Biologics disclosed a supply contract, worth US$260M, about 7.7% of its recent annual revenue, running through Dec 2033.
Supply contract · Sep 10 - Change in shares held by the largest shareholderSep 7
- [Amended] Investor relations (IR) meeting (notice)Sep 3
- [quarterly, individual company] Large business group status disclosureAug 31
- Operating results (consolidated) (preliminary) (fair disclosure)
Samsung Biologics filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$896M (+30.2% year on year), operating profit of US$398M (+22.9% year on year) and net income of US$292M (+29.1% year on year).
Earnings · Jul 23 - [Amended] Supply contract signed
Samsung Biologics updated a previously disclosed supply contract, now worth US$140M, about 46.48% of its recent annual revenue, running through Dec 2037.
Supply contract · Jun 22 - [Amended] Supply contract signed
Samsung Biologics updated a previously disclosed supply contract, now worth US$548M, about 18.38% of its recent annual revenue, running through Dec 2031.
Supply contract · Jun 17 - [Amended] Supply contract signed
Samsung Biologics updated a previously disclosed supply contract, now worth US$263M, about 8.81% of its recent annual revenue, running through Mar 2032.
Supply contract · Jun 9 · 3 versions - Operating results (consolidated) (preliminary) (fair disclosure)
Samsung Biologics filed provisional (unaudited) consolidated results for Q1 2026: revenue of US$851M (+25.8% year on year), operating profit of US$393M (+35% year on year) and net income of US$317M (+41.6% year on year).
Earnings · Apr 22 - [Amended] Decision to acquire shares/equity in another company (voluntary) (subsidiary)
Samsung Biologics updated the disclosed terms of a subsidiary's acquisition of Human Genome Sciences Inc., now worth US$347M.
M&A · Mar 31 - Rights offering (paid-in capital increase) decision (subsidiary)Capital raise · Mar 20
- Decision to acquire shares/equity in another company
Samsung Biologics disclosed an acquisition of Samsung Biologics America, Inc., worth US$352M.
M&A · Mar 20 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)Earnings · Jan 21
- Operating results (consolidated) (preliminary) (fair disclosure)Earnings · Jan 21